Abstract 5278
Background
We evaluated the impact of tumor type and molecular profiling on overall survival of patients (pts) with cancer referred to Medical Oncology Departments affiliated with the Hellenic Cooperative Oncology Group (HeCOG).
Methods
Pts referred from 1989 to 2017 had molecular testing (for research) of archival tumor tissue collected at the time of diagnosis (stage I-III, 82%; stage IV, 18%). Tumor-specific (e.g. breast, colon) gene panels (45-101 genes) were used to identify pathogenic mutations in clinically relevant genes. Deep sequencing was performed at the Laboratory of Molecular Oncology, Aristotle University of Thessaloniki and HeCOG. Mutation annotation was performed at MD Anderson Cancer Center. All pts received standard-of-care anticancer therapy.
Results
We analyzed 3,211 pts (median age, 58 years; men, 29%) with informative sequencing data. Results by tumor type and molecular pathway are shown in the table. Overall, 1,193 (37%) pts had ≥1 actionable alterations [115 (3.6%) ≥4]. The most common affected pathways were PI3K, RAF/MEK, homologous recombination repair (HRR), and tyrosine kinase; 294 (9.2%) pts had alterations in > 1 pathways. The median follow-up of alive patients is 7.48 years (yrs) (95%CI, 7.36-7.59). Of 3,211 pts, 1,060 (33.01%) have died. The median overall survival is 16.08 yrs (95%CI, 13.25-16.75). Of pts with breast cancer and actionable mutations, the 5-yr survival rates were: stage I-III (n = 501) 88.8%; stage IV (n = 14), 51.1% (p<.0001). Of pts with colorectal cancer and actionable alterations, the 5-yr survival rates were: stage I-III (n = 299), 76.5%; stage IV (n = 50), 15.2% (p<.0001).
Conclusions
Tumor sequencing revealed clinically relevant genomic mutations in several molecular pathways. Prospective clinical trials validating the clinical utility of tumor profiling are warranted.
Clinical trial identification
Legal entity responsible for the study
Hellenic Cooperative Oncology Group.
Funding
Hellenic Cooperative Oncology Group.
Editorial Acknowledgement
NA
Disclosure
All authors have declared no conflicts of interest.Table: 1876P
| Total N | N with actionable alterations | % | Overall Survival | ||
|---|---|---|---|---|---|
| Tumor type | Median, Years (95% CI) | 5-yr OS, % (95% CI) | |||
| Breast | 1,964 | 527 | 27 | NR | 87.8 (85.0-90.7) |
| Colorectal | 533 | 359 | 67 | NR | 68.0 (63.2-73.2) |
| Pancreatic | 188 | 123 | 65 | 0.82 (.65-.98) | - |
| Nasopharyngeal | 144 | 77 | 54 | 8.92 (6.68-NR) | 65.2 (54.7-77.7) |
| Brain | 131 | 24 | 18 | 4.54 (1.69-9.71) | 46.9 (29.9-73.6) |
| Gastric | 101 | 11 | 11 | 4.18 (1.04-NR) | 39.8 (17.8-88.9) |
| Biliary Tract | 80 | 26 | 33 | ND | |
| Ovarian | 70 | 46 | 66 | 3.24 (2.18-5.32) | 36.4 (24.7-53.5) |
| Total | 3,211 | 1,193 | 37 | 13.23 (10.6-NR) | 68.6 (65.9-71.4) |
| Pathway | Total tested | N with actionable alterations | % | ||
| PI3K/AKT/mTOR | 3,211 | 636 | 20 | 16.08 (13.23- NR) | 82.3 (79.3-85.4) |
| MEK/RAF | 3,211 | 459 | 14 | 6.4 (4.08-8.92) | 52.3 (47.7-57.3) |
| HRR | 3,211 | 260 | 8 | 7.84 (5.33-NR) | 56.8 (50.7-63.5) |
| Tyrosine kinase | 3,211 | 161 | 5 | NR | 69.2 (62.0-77.3) |
Resources from the same session
4293 - Prediction of response to vemurafenib in BRAF V600E mutant cancers based on a network approach
Presenter: Rosa Falcone
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4384 - Improving value for cancer patients: A European study of outcomes in practice
Presenter: Rishi Hazarika
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5485 - High-throughput screening of new drugs targeting lung CSCs
Presenter: Héctor Amado Labrador
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4218 - RING observational trial to compare T790M mutation testing in blood by different methodologies
Presenter: Beatriz Garcia-Pelaez
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2775 - Indicators of non-participation in cervical cancer screening: Results from the EDIFICE 6 survey
Presenter: Thibault de La Motte Rouge
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5852 - Tolerance and efficacy of immune-checkpoint inhibitors for cancer in people living with HIV (PWHIV)
Presenter: Aurélien Gobert
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
819 - Effects of physical exercise in non-operable lung cancer patients undergoing palliative treatment
Presenter: Joachim Wiskemann
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract